Poloxamer Micelle Encapsulation of Cationic Steroidal Antimicrobials
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Ciliated tissues face challenges in treating biofilm infections due to the cytotoxicity of high concentrations of cationic steroidal antimicrobial (CSA) compounds, which are effective against microbes but can damage fragile cilia, and the instability of CSA compounds leading to reduced efficacy.
Innovation Solution
Forming micelles using a poloxamer surfactant like PLURONIC F127 to encapsulate CSA compounds, reducing agglomeration and cytotoxicity while maintaining antimicrobial activity, allowing higher CSA concentrations to be used without harming cilia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher concentrations of CSA compounds are used to eradicate biofilm pathogens, then antimicrobial efficacy is improved, but cytotoxicity to ciliated cells increases
Solution Approach 1:
The patent uses micelle-forming amphiphilic compounds as intermediaries to deliver CSA compounds to microbial membranes while preventing direct contact with ciliated cells. The micelles act as carriers that selectively release CSA at the microbial interface, enabling high concentration delivery without proportional increase in cytotoxicity to host tissues.
Solution Approach 2:
The patent changes the physical state and delivery parameters of CSA compounds by incorporating them into micellar structures. This alters the local concentration distribution, allowing high overall concentrations to be maintained while controlling local exposure at sensitive tissue interfaces, thereby decoupling efficacy from cytotoxicity.
2Reliability
If CSA compounds are administered in high concentrations to treat biofilm infections, then pathogen eradication is improved, but cilia damage and detachment increase
Solution Approach 1:
Micelle-forming compounds serve as protective intermediaries that shield cilia from direct exposure to high concentrations of CSA. The micelles preferentially interact with microbial membranes due to their amphiphilic nature, allowing effective pathogen eradication while the cilia remain protected from direct contact with the cytotoxic agent.
Solution Approach 2:
The patent achieves localized delivery of high CSA concentrations specifically at the microbial interface while maintaining lower effective concentrations at ciliated tissue interfaces. This spatial differentiation of concentration allows effective pathogen killing without proportional damage to cilia, as the micelles concentrate CSA where it is most needed.
3Reliability
If CSA compounds are used at high concentrations to ensure complete biofilm elimination, then treatment effectiveness is improved, but safety margin to mammalian tissues is reduced
Solution Approach 1:
The micelle-forming amphiphilic compounds act as safety-intermediaries that enable the use of high CSA concentrations for complete biofilm elimination while protecting mammalian tissues. The micelles control the release and localization of CSA, ensuring that high concentrations are present only where needed for treatment effectiveness while maintaining a safety margin at mammalian tissue interfaces.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The micelle-forming approach effectively kills microbes, including biofilm forms, without significantly disrupting ciliary function, enabling the use of higher CSA concentrations for effective treatment while minimizing damage to ciliated cells.
Implementation Method 1
forming micelles within the solvent or carrier liquid using a suitable micelle-forming amphiphilic compound or composition that is able to encapsulate the CSA molecules and reduce or prevent agglomeration within the composition
Implementation Method 2
the mechanism of decreased toxicity to ciliated cells is due to transient encapsulation of CSAs in micelles formed by the poloxamer. While ensconced in micelles, CSAs are less prone to associate with host membranes, yet retain high affinity to microbial membranes
Data Source
AI summary
The present disclosure describes treatment compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. The method utilizes a treatment composition that includes a cationic steroidal antimicrobial (CSA) compound, a poloxamer, and a carrier, which is administered to ciliated tissue, such as lung tissue, in order to prevent or treat a microbial infection by killing microbes associated with the ciliated tissue. The poloxamer forms micelles that encapsulate the CSA compound, the poloxamer being included in the treatment composition in an amount, by weight, that is about 100 to 1000 times the amount of the CSA compound.